BISPECIFIC T-CELL ENGAGER
Tecvayli is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory multiple myeloma in adults who have already tried at least four lines of therapy. These previous therapies must include a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli may be referred to by its drug name, teclistamab-cqyv.
Tecvayli is a bispecific T-cell engager. The drug consists of a genetically engineered protein, or antibody, that targets the B-cell maturation antigen (BCMA) on B cells — including myeloma cells — and the CD3 protein on T cells. Tecvayli is believed to work by prompting T cells to kill myeloma cells.
How do I take it?
Tecvayli is administered as a subcutaneous (under the skin) injection once a week after loading doses (initial large doses). Tecvayli comes in the form of a single-dose vial.
The FDA-approved label for Tecvayli lists common side effects including cytokine release syndrome (CRS), a potentially fatal inflammatory reaction that causes severe neurological symptoms such as hallucinations and tremors. Other common side effects are fever, injection site reactions, fatigue, upper respiratory tract infections, nausea, headache, pneumonia, diarrhea, and pain in the muscles, bones, or joints.
Other rare but serious side effects listed for Tecvayli include liver damage and infections (both of which may be severe or even life-threatening), hypersensitivity reactions, and fetal harm.
For more details about this treatment, visit:
Tecvayli — Janssen Biotech Inc.